ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Athira Pharma Inc

Athira Pharma Inc (ATHA)

0.617
-0.028
( -4.34% )
Actualizado: 14:48:06

Herramientas de nivel profesional para inversores individuales.

Estadísticas y detalles clave

Último Precio
0.617
Postura de Compra
0.617
Postura de Venta
0.6313
Volume Operado de la Acción
114,218
0.6107 Rango del Día 0.6628
0.4115 Rango de 52 semanas 4.2984
Capitalización de Mercado [m]
Precio Anterior
0.645
Precio de Apertura
0.6377
Última hora de negociación
14:50:05
Volumen financiero
US$ 71,881
Precio Promedio Ponderado
0.629333
Volumen promedio (3 m)
5,102,123
Acciones en circulación
38,669,073
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.20
Beneficio por acción (BPA)
-3.04
turnover
1.63M
Beneficio neto
-117.67M

Acerca de Athira Pharma Inc

Athira Pharma Inc is a biotechnology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease. Athira Pharma Inc is a biotechnology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease.

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Athira Pharma Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ATHA. The last closing price for Athira Pharma was US$0.65. Over the last year, Athira Pharma shares have traded in a share price range of US$ 0.4115 to US$ 4.2984.

Athira Pharma currently has 38,669,073 shares in issue. The market capitalisation of Athira Pharma is US$24.94 million. Athira Pharma has a price to earnings ratio (PE ratio) of -0.20.

ATHA Últimas noticias

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting

BOTHELL, Wash., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.0007-0.113323619880.61770.67890.62957750.64608365CS
4-0.0224-3.503284329060.63940.82640.614687730.72571822CS
120.15232.6881720430.4650.82640.411551021230.60418454CS
26-1.993-76.36015325672.613.670.411526975490.67935793CS
52-0.863-58.31081081081.484.29840.411515282900.90755551CS
156-12.503-95.297256097613.1214.220.41157413292.11611415CS
260-19.333-96.907268170419.9534.790.41156853675.13327511CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
AALAmerican Airlines Group Inc
US$ 0.00
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
US$ 0.00
(0.00%)
0
AACGATA Creativity Global
US$ 0.00
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 0.00
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
US$ 0.00
(0.00%)
0
AACGATA Creativity Global
US$ 0.00
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 0.00
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.00
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 0.00
(0.00%)
0
AADIAadi Bioscience Inc
US$ 0.00
(0.00%)
0
AACGATA Creativity Global
US$ 0.00
(0.00%)
0

ATHA Discussion

Ver más
Rocket-Interceptor Rocket-Interceptor 4 semanas hace
just amazing
👍️0
glenn1919 glenn1919 4 semanas hace
ATHA................................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 4 semanas hace
ATHA...........................................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 1 mes hace
ATHA TO A DOLLAR
👍️0
glenn1919 glenn1919 1 mes hace
ATHA...........................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783
👍️ 1
stockyupydowny stockyupydowny 3 meses hace
Some life coming back into play with this one, the 400 million cash injection deal that takes the to the $1 billion dollar deal they made will be reflected with patience
👍️ 1
Saving Grace Saving Grace 3 meses hace
ATHA under .65 cents and plunging.
👍️0
Monksdream Monksdream 3 meses hace
ATHA under $4
👍️0
Monksdream Monksdream 4 meses hace
ATHA under $3
👍️0
Monksdream Monksdream 6 meses hace
ATHA under $3
👍️0
glenn1919 glenn1919 8 meses hace
ATHA..............................https://stockcharts.com/h-sc/ui?s=ATHA&p=W&b=5&g=0&id=p86431144783
👍️0
Awl416 Awl416 9 meses hace
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
👍️0
Whalatane Whalatane 10 meses hace
4:22 PM ET 02/14/2024
http://archive.fast-edgar.com/20240214/A3BEF62C8M22CZZ2222M2ZZZ5PKQZ2U2X262
Filed on: February 14, 2024

Baker Bros position
-------
Kiwi
👍️0
Whalatane Whalatane 11 meses hace
“The new year is off to a strong start with the completion of enrollment in our Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease (AD), which we expect will enable topline data readout from the study in the second half of 2024,” said Mark Litton, Ph.D., President and Chief Executive Officer of Athira.
“The potential of fosgonimeton as a treatment for AD is supported by the independent, unblinded interim efficacy and futility analysis of the first 100 subjects in the Phase 2/3 LIFT-AD study and the results from the exploratory Phase 2 ACT-AD clinical trial, which showed potential congruent improvements in biomarkers of neurodegeneration, inflammation and Alzheimer’s disease protein pathologies as well as measures of cognition and function.”

“The totality of data shared to date strengthens our confidence in and supports the potential of our small molecule approach to targeting the neurotrophic hepatocyte growth factor (HGF) system for diseases including Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). The consistency of data from preclinical models across various neurodegenerative diseases and in Alzheimer’s patients suggests that our small molecule drug candidates may be neuroprotective, neurotrophic, procognitive and potentially disease-modifying. This includes our recently reported findings from the exploratory SHAPE Phase 2 clinical trial, the results of which showed positive effects on several cognitive measures in the fosgonimeton 40 mg dose group, which is the same dose being investigated in the LIFT-AD trial.”


Kiwi
👍️0
Whalatane Whalatane 11 meses hace
ATHA their P2/3 Alzheimer trial now fully enrolled.
Data in about 9 mths
They had an interim analysis run by an independent DMC ....Did not stop for futility . DMC said increase size of trial to power for statistically significant results ....so trial likely to show benefit .
Question is ....will the degree of benefit be clinically relevant .
-------------
Kiwi
👍️0
Whalatane Whalatane 11 meses hace
The Trade: Athira Pharma, Inc. (ATHA) Director Joseph Edelman acquired a total of 605,686 shares at an average price of $2.42. To acquire these shares, it cost around $1.46 million.
What's Happening: Athira Pharma (ATHA), last month, announced results from SHAPE Phase 2 clinical trial of fosgonimeton for the treatment of Parkinson's disease dementia and dementia with Lewy Bodies.
What Athira Pharma Does: Athira Pharma Inc (ATHA) is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration.

Kiwi
👍️0
TrendTrade2016 TrendTrade2016 3 años hace
ATHA... what a bio beast running through the streets...watch the explosion on the horizon...
👍️0
TrendTrade2016 TrendTrade2016 3 años hace
What a day…what a stock!!!
👍️0
great_tree great_tree 3 años hace
Any serious comments on their product vs. SAVA, CRTX, AVXL etc.?
👍️0
TrendTrade2016 TrendTrade2016 3 años hace
ATHA pushing hard into close
👍️0
TrendTrade2016 TrendTrade2016 3 años hace
ATHA bio beast is very mad. She wants to fill that gap
👍️0
TrendTrade2016 TrendTrade2016 3 años hace
ATHA is ready to move big next week, the best bio taking on Alzheimers
👍️0
TrendTrade2016 TrendTrade2016 3 años hace
ATHA starting to heat up..love this bio beast!!!
👍️0
TrendTrade2016 TrendTrade2016 3 años hace
ATHA another bio beast ready to beast
👍️0
maximumgriff maximumgriff 3 años hace
Girt prices
👍️0
crudeoil24 crudeoil24 4 años hace
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform (ATH) platform, and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. The ATH platform utilizes proprietary technology to target and enhance the activity of a vital neuronal growth factor that promotes neuronal health and regeneration. The Company is developing ATH-1017, for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). ATH-1017 is designed to enhance neuronal health and promote regeneration, thereby improving symptoms in cognitively impaired subjects.
👍️0
crudeoil24 crudeoil24 4 años hace
Athira Pharma started at buy with $36 stock price target at Stifel Nicolaus.
👍️0

Su Consulta Reciente

Delayed Upgrade Clock